The Supreme Court ruled that the maker of Roundup weedkiller cannot face failure-to-warn lawsuits in state courts, handing a major victory to Bayer in the long-running cancer litigation. The court found that federal regulations have deemed a cancer link unlikely and do not require a warning label, undercutting the legal basis for those state-level claims.
What the Supreme Court decided
The ruling is expected to block thousands of lawsuits alleging that agrochemical manufacturer Bayer failed to warn consumers that Roundup could cause cancer. Bayer continues to dispute the cancer claims, but it has already set aside enormous sums to resolve the wave of litigation tied to glyphosate, the herbicide's longtime active ingredient.
- Bayer previously set aside $16 billion to settle cases.
- Earlier this year it proposed a $7.25 billion class-action settlement.
- It also removed glyphosate as an ingredient from Roundup sold in the US.
By shielding the company from state failure-to-warn suits, the decision removes one of the main legal theories plaintiffs have used to pursue damages, and it could reshape how product-liability claims against federally regulated pesticides proceed nationwide.
The political fault lines
The decision aligns with the public position of the Trump administration, but it also exposes cracks between the MAGA movement and the Make America Healthy Again (MAHA) wing, the latter of which has pushed to rein in pesticide use. That tension highlights how questions about agricultural chemicals increasingly cut across, rather than along, traditional party lines.
Other health headlines making news
The ruling landed during a busy stretch for health policy. Democratic lawmakers are publicly pressing the administration over a 79-year-old patient who received special access in April to retatrutide, Eli Lilly's experimental obesity drug, asking whether the recipient is the president. Sen. Maggie Hassan (D-N.H.) sent a letter seeking the patient's identity, while Rep. Ted Lieu (D-Calif.) suggested the drug's side effects may have factored into a cancelled bill signing.
Elsewhere, researchers reported that a next-generation genome-editing tool tested in early embryos appears more precise and less destructive than earlier CRISPR, deepening the ethical debate over editing human embryos. Public health officials are also tracking medetomidine, a powerful tranquilizer now turning up alongside fentanyl in the illicit opioid supply and causing severe withdrawal in jails, where it has been detected across 20 sites with the highest prevalence in the Northeast.
What it means for the broader fight
On the policy front, the Trump administration is weighing tighter control over the Centers for Disease Control and Prevention through a proposed Executive Advisory, Science, and Operations Unit that would review the agency's scientific publications and briefings, though no funding has yet been secured. A new charter for the Advisory Committee on Immunization Practices (ACIP) has also taken shape, reshaping the panel's role in recommending new vaccines.
Taken together, the Roundup ruling and these developments underscore how courts, regulators and lawmakers are simultaneously redrawing the lines around drug access, chemical safety and public health oversight in the United States.
Frequently asked questions
What did the Supreme Court rule about Roundup?
The court held that Bayer cannot be sued in state courts for failing to warn that Roundup could cause cancer, because federal regulation has not required such a warning, a finding expected to block thousands of pending claims.
How much has Bayer set aside for Roundup litigation?
Bayer previously earmarked $16 billion to settle cases and this year proposed a $7.25 billion class-action settlement, while also removing glyphosate from Roundup sold in the US. For continuing coverage of courts, drugs and public health, see our health news hub and the latest in the newsroom.
